Table 2.
Correlation of ZO-1 Immunostaining with Histopathology and E-Cadherin Immunostaining in Patients with Breast Cancer
| Total | ZO-1 Rd | P Value | ||||
|---|---|---|---|---|---|---|
| ZO-1 Positive | ZO-1 Reduced | ZO-1 Negative | Subtotal | |||
| Tumor type | *.0024 | |||||
| Infiltrating ductal | 38 | 10 (26.3%) | 14 | 14 | 28 (73.7%) | |
| Ductal carcinoma in situ | 5 | 5 (100%) | ||||
| Infiltrating lobular | 3 | 0 | 3 | 3 (100%) | ||
| Lobular carcinoma in situ | 2 | 0 | 2 | 2 (100%) | ||
| Total | 48 | 15 (31.2%) | 16 | 17 | 33 (68.8%) | |
| Tumor grade† | *.011 | |||||
| Well | 12 | 7 (58.3%) | 4 | 1 | 5 (41.7%) | |
| Moderate | 12 | 2 (16.7%) | 4 | 6 | 10 (83.3%) | |
| Poor | 14 | 1 (7.1%) | 6 | 7 | 13 (92.9%) | |
| Glandular differentiation† | *.0019 | |||||
| 1 | 10 | 7 (70.0%) | 3 | 0 | 3 (30.0%) | |
| 2 | 5 | 0 | 5 | 0 | 5 (100%) | |
| 3 | 22 | 3 (13.6%) | 6 | 13 | 19 (86.4%) | |
| E-cadherin staining | *‡4.9 × 10−5 | |||||
| Positive | 26 | 14 (53.8%) | 10 | 2 | 12 (46.2%) | |
| Reduced | 12 | 0 | 4 | 8 | 12 (100%) | |
| Negative | 8 | 0 | 0 | 8 | 8 (100%) | |
| Rd (reduced+ negative) | 20 | 0 | 4 | 16 | 20 (100%) |
*Statistically significant.
†Scarff-Bloom-Richardson histopathological staging.
‡Significance level of the correlation between E-cadherin and ZO-1 Positive and Rd type staining.